Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 90,663-QQ

Serial No.

10/050,271

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Yatvin et al.

Filing Date: 1-15-2002

Group: 1651

U.S. PATENT DOCUMENTS

Examiner Initial		Do	ocu	men	it N	uml	oer		Date	Name	Class	Subclass	Filing Date if Appropriate
on		5	4	3	4	1	3	7	7-18-95	Black			
1		5	0	1	7	5	6	6	5-21-91	Bodor			·
		5	0	2	4	9	9	8	6-18-91	Bodor			
		5	1	7	7	0	6	4	1-5-93	Bodor			
		5	3	8	9	6	2	3	2-14-95	Bodor			
		5	4	1	3	9	9	6	5-9-95	Bodor			
		5	5	2	5	7	2	7	6-11-96	Bodor			,
		5	4	0	5	8	3	4	4-11-95	Bundgaard			
		5	1	5	3	1	7	9	10-6-92	Eibl			
		5	0	5	3	3	9	4	10-91	Ellestad			
		5	4	4	2	0	4	3	8-15-95	Fukata			
	T	5	2	7	0	3	1	2	12-14-93	Glase			
		5	1	1	2	8	6	3	5-12-92	Hashimoto			
		5	0	2	3	2	5	2	6-11-91	Hseih			
		5	2	5	8	4	5	3	11-93	Kopecek			
	†	4	7	8	0	4	5	5	10-25-88	Liberman			
		5	1	2	4	1	4	6	6-23-92	Neuwelt			
	 	4	8	4	7	2	4	0	7-89	Ryser			
		4	7	9	3	9	8	6	12-88	Serino	1		·
		5	2	8	4	8	7	6	2-8-94	Shashoua			
	T	5	2	5	4	3	4	2	10-19-93	Shen			
		5	4	6	6	6	8	3	11-14-95	Sterling			
am	-	5	0	3	9	7	9	4	8-13-91	Wier			
Examiner		<u>}</u>	\leq		>_		M	・ベ	M	Date Considered	119/01	f	

Form PTO-1449 INFORMATIO STATEMENT	Pate N DISC	ent and	i Tra IRE	of Commerce demark Office		Serial No. 10/050,271
					Applicant: Yatvin et al.	
					Filing Date: 01-15-2002	Group: 1651
			U	.S. PATENT	DOCUMENTS	
on 514	9 7	9	4	9-22-92	Yatvin	
5 5 4	3 3	8	9	8-6-96	Yatvin	
en 5 5 4	3 3	9	0	8-6-96	Yatvin	
5 2 5	6 6	4	1	10/1993	Vation etal	
5 5 4	0 6	7	4	1 -	Vadvin et l	
606	3 7	5	9	3/2000	Latin Al	

FOREIGN PATENT DOCUMENTS

				Docu	ment N	lumbe	er			Date	Country	Class	Subclass	Transl	ation
														Yes	No
Dr.		_1	EP	0	7	7	5	2	9	4/27/83					
		2	EP	1	0	9	4	8	4	4/83					
		3	EP	2	0	3	6	7	6	12/3/86					
		4	EP	2	7	9	8	8	7	8/31/88		7			
		5	EP	3	0	1	2	2	3	12/83					
	П	6	EP	3	5	0	2	8	7	1/10/90					
	П	7	wo	85	0	2	3	4	2	6/6/85					
П	Į.	8	wo	89	0	0	1	6	6	11/89					
a	~	9	wo	89	0	2	9	0	9	1/90					
E	xaı	min_			f	М.	S	H		Date Consi	dered 4/19	104			

	form P	Orm PTO-1449 U.S. Department of Commo Patent and Trademark Of INFORMATION DISCLOSURE STATEMENT BY APPLICANT									cket No.		Serial No. 10/050,271		
										Applicar	nt: Yatvin et a	l.			
										Filing Da	ate: 1-15-200)2	Group: 1	651	
an	10	wo	89	1	0	3	4	8	11/2	/89		 ,			
	11	wo	89	1	1	2	9	9	11/3	0/89					
	12	wo	90	0	0	5	5	5	1/25	/90					
	13	wo	90	0	1	0	0	2	9/90						
Ш	14	wo	90	0	4	0∼	8	7	2/91						
Ц	15 WO 90 1 0 4 4 8 9								9/20	/90					
	16	wo	91	0	1	7	. 5	0	2/21	/91					
	17	wo	91	0	2	6	9	1	10/9	1					
	18	wo	91	0	4	0	1	4	4/4/	91					
	19	wo	91	0	4	7	4	5	4/18	/91					
	20	wo	91	1	4	4	3	8	10/3	/91					
	21	wo	91	1	6	0	2	4	10/3	1/91					-
	22	wo	91	1	6	0	2	4A	10/3	1/91					
	23	wo	91	1	9	7	2	6A	12/2	6/91	-		-		
Ш	24	wo	94	0	1	1	3	1	1/20	/94					
	25	wo	94	0	1	1	3	8	1/20	/94					
	26	wo	94	0	2	1	7	8	2/3/	94					
1	27	wo	94	0	3	4	2	4	2/17	/94					
	Exami	ner <	5	Q	\sum_{i}	W	()	4		Date Col	nsidered	, _P			

	Fo	rm PT		NFORM	IATION MENT B	DISCL	nt and	Trade RE			Atty. Do	cket No.		Serial No. 10/050,271		
											Applicar	nt: Yatvin et a	l.			
											Filing Da	ate: 1-15-200)2	Group: 1	651	
R	m	28	wo	91	1	9	7	2	6A	12/2	6/91					
		29	wo	94	0	1	1	3	1	1/20/	/94	·				
L	Ц	30	wo	94	0	1	1	3	8	1/20/	/94					
	Ш	31	wo	94	0	2	1	7	8	2/3/9)4	. —				
		32 WO 94 0 3 4 2						4	2/17/	/94		>				
L	Ш	33	wo	94	0	6	4	5	0	3/31/	/94		->			
		34	WO	94	0	1	1	3	8	1/20/	/94					
L		35	wo	94	2	5	6	1	6	11/10	0/94					
		36	wo	95	0	7	0	9	2	3/16/	/95					
		37	wo	95	2	2	9	6	3	8/31/	/95					
		38	wo	95	3	2	0	0	2	11/30	0/95			-		
	\parallel	39	wo	96	0	0	5	3	7,	1/11/	/96					
	\prod	40	wo	96	0	4	0	0	1	2/15/	/96	×				
þ	**	41	wo	96	2	2	3	0	3	7/25/	/96					
	Ex	amii	ner	6		Ж	, (y	1		Date Cor	nsidered +/19/	lo J			

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 90,663-QQ Applicant: Yatvin et al.	Serial No. 10/050,271
	Filing Date: 1-15-2002	Group: 1651
42 Abbas et al., "Antigen Presentation and T Ce (W.B. Saunders Co.; Philadelphia), pp. 116-1		ular as J. Mol. Immunol.
43 Afzelius et al., Biochim. Biophys. Acta 979:	231-238 (1989)	
44 Alvarez-Dominquez et al., "Role of Compler monocytogenes by Murine Macrophage-Like		- I
45 Anderson et al., J. Am. Chem. Soc. <u>85</u> : 3039	(1963)	
46 Ashborn et al., "Anti-HIV Activity of CD4-P Lympocytes and Monocyte/Macrophages," J.		
47 Baer, Can. J. Biochem. Phys. <u>34</u> : 288-304 (19	955)	
48 Bai and Amidon, "Structural Specificity of M. Drugs: Implications for Oral Peptide Drug D		
Examiner	Date Considered 4/19/0	/

				T T
Form	PTO-1	U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 90,663-QQ	Serial No. 10/050,271
			Applicant: Yatvin et al.	
			Filing Date: 1-15-2002	Group: 1651
San	49	Bai et al., "Utilization of Peptide Carrier Syst Prolidase as a Prodrug-Converting Enzyme,"	tem to Improve Intestinal Absorb. J. Pharm. Sci. 81: 113-116 (1	orption: Targeting 1992)
	50	Barlow et al., "Mast cells and T lymphocytes 25: 317-322 (1995)	in chronic urticaria," Clinical	& Experimental Allergy
	51	Baroni et al., "Expression of HIV in Lymph N Hybridization, and Identification of Target Co	Node Cells of LAS Patients: In Ells," Am. J. Pathol. 133: 498	mmunohistology, In Situ -506 (1988)
	52	Berdel et al., <i>Lipids</i> 22: 943-946 (1987)		
	53	Bickel et al., "Pharmacologic effects in vivo in Natl. Acad. Sci. USA 90: 2618-2622 (1993)	n brain by vector-mediated pe	ptide drug delivery," Proc.
	54	Blakey, "Drug Targeting with Monoclonal Ar	ntibodies," Acta Oncol. 31: 91	1-97 (1992)
	55	Blight et al., "Detection of hepatitis C virus R	NA by in situ hybridization,"	Liver <u>12</u> : 286-289 (1992)
	56	Blum et al., "Bloood clearance and organ dep the effects of particle size, nature and shape,"	osition of intravenously admir ' Int. J. Pharm. 12: 135-146	nistered colloidal particles: (1982)
	57	Boehnlein et al., "Characterization of Esterase Metabolism of Retinyl Palmitate to Retinol (V Pharmaceutical Research 11: 1155-1159 (19	Vitamin A) During Percutaneo	Activity in Skin. ous Absorption,"
	58	Boman et al., "Cell-free immunity in Cecropia Biochem. 201: 23-31 (1990)	a: A model system for antibac	cterial proteins," Eur. J.
	59	Borissova et al., "Biodegradable Microsphere Spacer Arms," Journal of Pharmaceutical Sci	s. 17. Lysosomal Degradation iences, Vol. 84, No. 2, Februar	of Primaquine-Peptide ry 1995, pages 256-262
	60	Bou-Gharios et al., "Expression of ectopeptid 111-116 (1995)	ases in scleroderma," Annals o	of Rheumatic Disease <u>54</u> :
	61	Brewster et al., "Improved Delivery through E Stabilization of an Estradiol Chemical Deliver 77: 981-985 (1985)	Biological Membranes XXXI: ry System by Modified β-Cycl	Solubilization and lodextrins," J. Pharm. Sci.
	62	Bromberg et al., "Detection of Borditella pert Children with Human Immunodeficiency Viru	is Infection," Infect. Immun. 5	eolar Macrophages of 9: 4715-4719 (1991)
	63	Brown & Silvius, Biochim. Biophys. Acta 102	<u>3</u> : 341-351 (1990)	
	64	Brown et al., "Induction of Cell Surface Peptic Correlated with Apoptosis," J. Cellular Bioch	dase Acitivity: A Global Resp themistry <u>54</u> : 320-331 (1994)	oonse to Cell Stress
	65	Brynestad et al., J. Virol. 64:680-685 (1990)		

0	W	66	Buchmeier and Heffron, "Induction of Salmonella Stress Proteins upon Infection of Macrophages," Science 248: 730-732 (1990)
a	^	67	Büyüktimkin et al., "Synthesis and Enhancing Effect of Dodecyl 2-(N,N-Dimethylamino)propionate on the Transepidermal Delivery of Indomethacin, Clonidine, and Hydrocortisone," <i>Pharmaceutical Research</i> 10: 1632-1637 (1993)
Ex	amir) (Date Considered 4/19/04

		Atty. Docket No. 90,663-QQ	Serial No. 10/050,271			
•		Applicant: Yatvin et al.				
		Filing Date: 1-15-2002	Group: 1651			
68 Chang, "Leishmania don Parisitol. 48:175-189 (1)		e-Macrophage Surface In	nteractions in Vitro," Exp.			
69 Clarke et al., "Detection AIDS 4: 1133-1136 (199		n lung macrophages using the polymerase chaine reaction,"				
70 Comiskey & Heath, Biod	chim. Biophys. Acta <u>1</u>	024: 307-317 (1990)				
71 Cordier et al., "In vivo A Immunol. Immunopathol			Lentivirus Infection," Clin.			
72 Couveur and Puisieux, " Drug Deliv. Rev. 10: 14		particles for the delivery of polypeptides and proteins," Adv.				
73 Dachun et al., "Localizat of Wounds," Forensic So			sterase in Injured Skin for Timing			
74 De Magistris et al., "Ant T Cell Receptor," Cell 6		Histocompatibility Complexes Act As Antagonists of the				
75 Debs et al., Biochim. Bio	phys. Acta <u>901</u> : 183	83-190 (1987)				
76 Deres et al., Nature 342:	561-564 (1989)					
77 Dreyer et al., Proc. Natl.	Acad. Sci. USA 86:	9752-9756 (1989)				
78 Duncan, "Drug-polymer 175-210 (1992)	conjugates: potentia	l for improved chemoth	erapy," Anticancer Drugs 3:			
79 Elliott et al., "Naturally p	processed peptides,"	Nature <u>348</u> : 195-197 (1	990)			
80 Embretson et al., "Massi during the incubation per			and macrophages by HIV			
81 Falk et al., "Allele-specif molecules," Nature 351:	fic motifs revealed by		tides eluted from MHC			
82 Falk et al., "Cellular pep molecules," Nature 348:		erned by major histocor	mpatibility complex class I			
83 Faulk et al., "Transferrin Interaction with DNA In Biochem. Int. 25: 815-82	hibit Plasma Membra	ates which Inhibit Tumo ane Oxidoreductase and	or Cell Proliferation without Proton Release in K562 Cells,"			

Fo	orm I	PTO-1	U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 90,663-QQ	Serial No. 10/050,271
				Applicant: Yatvin et al.	
				Filing Date: 1-15-2002	Group: 1651
75		84	Faustman et al., "Linkage of Faulty Major Hi Diabetes," Science 254: 1756-1776 (1991)	stocompatibility Complex Cla	ss I to Autoimmune
		85	Franssen et al., "Low Molecular Weight Prote Drug-Protein Conjugates and Drug-Spacer De Homogenates and Lysosomal Lysates," <i>J. Me</i>	erivatives and Their Catabolis	m in Renal Cortex
		86	Frehel et al., Intramacrophage Growth of Myo Immun. 59: 2207-2214 (1991)	cobacterium avium during Info	ection of Mice," Infect.
		87	Friedman et al., "Uptake and Intracellular Sur Infect. Immun. 60: 4578-4585 (1992)	rvival of <i>Bordatella pertussis</i>	in Human Macrophages,"
		88	Frisch et al., "Parameters affecting the immur hexapeptide antigen," Eur. J. Immun. 21: 18:	• •	ciated synthetic
		89	Gaspar et al., "Drug targeting with polya primaquine-loaded nanoparticles against in <i>Parasitol</i> . 86: 41-49 (1992)		
		90	Gendelman et al., "Slow, persistent replication macrophage precursors in bone marrow," Pro-		1 0
		91	Germain & Hendrix, "MHC class II structure endoplasmic reticulum antigen binding," Nati	• •	ssion determined by post-
d	M	92 (Groisman et al., "Resistance to host antimicro <i>Proc. Natl. Acad. Sci. USA</i> 89: 11939-11943	· ·	Salmonella virulence,"
Ex	amiı	ner	M. 44.	Pate Considered	

Form F	PTO-14	U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 90,663-QQ	Serial No. 10/050,271
			Applicant: Yatvin et al.	
			Filing Date: 1-15-2002	Group: 1651
211	93	Guéry et al., "Selective Immunosuppression Complex (MHC) Class II-binding Peptides Cell Activation," J. Exp. Med. 175: 1345-1	. I. Evidence for In Vivo MH	
	94	Halstead et al., "Dengue Viruses and Mono Neutralizing Antibody," J. Exp. Med. 146:2	nuclear Phagocytes: I. Infecti	on Enhancement by Non-
	95	Hashimoto et al., Biochim. Biophys. Acta 8	<u>16</u> : 163-168 (1985)	
Π	96	Hashimoto et al., Biochim. Biophys. Acta 8	<u>16</u> : 169-178 (1985)	
71 1	97	Heath and Martin, Chem. Phys. Lipids 40:	347-358 (1986)	
	98	Heath et al., Biochim. Biophys. Acta 862: 73	2-80 (1986)	
	99	Heath, Methods in Enzymol. 149: 111-119		*****
	100	Heinrich et al., "In-vivo Release of a GnRH Copolymer Preparation: Comparison in Ra 762-765 (1991)	_	,
	101	Henrikus and Kampffmeyer, "Ester hydroly homogenate, and by liver esterase of rabbits		
	102	Heymann et al., "Organophosphate Sensitiv Chem. Biol. Interactions 87: 217-226 (199)		erases in Human Skin,"
	103	Hopp, "Immunogenicity of a Synthetic HBs Acid Carrier," <i>Mol. Immunol.</i> 21: 13-16 (1	~ .	Conjugation to a Fatty
	104	Horwitz and Maxfield, "Legionella pneump Monocytes," J. Cell Biol. <u>99</u> : 1936-1943 (1		its Phagosome in Human
	105	Horwitz, "Interactions between Macrophage Immunol. 181:265-282 (1992)	es and Legionella pneumophil	a," Curr. Top. Microbiol.
	106	Horwitz, "The Legionnaires' Disease Bacte Lysosome Fusion in Human Monocytes," J.	` • •	, -
	107	Hostetler et al., J. Biol. Chem. 265: 6112-6	117 (1990)	
	108	Hunter et al., "Vesicular Systems (Niosome Stibogluconate in Experimental Murine Vis 165 (1988)		
Jul.	109	Jacobson et al., FEBS Lett. 225: 97-102 (19	987)	

S	1	110	Jardetzky et al., "Identification of self peptides bound to purified HLA-B27," Nature 353: 326-329 (1991)				
\prod		111	Jones and Hirsch, "The Interaction between <i>Toxoplasma gondii</i> and Mammalian Cells," <i>J. Exp. Med.</i> , 136:1173-1194 (1972)				
		112	Kanno et al., "Aleutian Mink Disease Parvovirus Infection of Mink Peritoneal Macrophages and Human Macrophage Cell Lines," J. Virol. 67:2075-2082				
П		113	Kanno et al., "Identification of Aleutian Mink Disease Parvovirus Transcripts in Macrophages of Infected Adult Mink," J. Virol. 66:5305-5312 (1992)				
П		King et al., "In Vivo Selection of Lymphocyte-Tropic and Macrophage-Tropic Variants of Lymphocytic Chorimeningitis Virus during Persistent Infection," J. Virol. 64: 5611-5616 (1990)					
П		115	Kinsky & Loeder, Biochim. Biophys. Acta 921: 96-103 (1987)				
П		116	Kinsky et al., Biochim. Biophys. Acta 885: 129-135 (1986)				
П		117	Kinsky et al., Biochim. Biophys. Acta 917: 211-218 (1987)				
П		118	Kishimoto, Chem. Phys. Lipids 15: 33-36 (1975)				
te	Koenig et al., "Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients with Encephalopathy," Science 233: 1089-1093 (1986)						
E	Examin r W. M. Date Considered 1/9/04						

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Patent and Trademark Office INFORMATION DISCLOSURE	Atty. Docket No. 90,663-QQ Applicant: Yatvin et al.	Serial No. 10/050,271
				Filing Date: 1-15-2002	Group: 1651
2		120	Kondo et al., "Latent human herpesvirus 6 Virol. 72: 1401-1408 (1991)	infection of human monocytes	/macrophages," J. Gen.
	121 Koval & Pagano, "Lipid Recycling between the Plasma Membrane and Intracellular Compartments: Transport and Metabolism of Fluorescent Sphingomyelin Analogues in Cultured Fibroblasts," J. Cell Biol. 108: 2169-2181 (1989)				
	122 Kratz et al., "Keratinocyte conditioned medium stimulates type IV collagenase synthesis in culture human keratinocytes and fibroblasts," <i>Brit. J. Dermatology</i> 133: 842-846 (1995)				
	123 Kreeger, The Scientist, September 16, 1996			б, р. б	
		124	Krowka et al., J. Immunol. 144: 2535-2540	0 (1990)	
	125 Kubota et al., "Metabolism and Degradation of Betamethasone 17-Valerate in Homogenized Livi Skin Equivalent," <i>Dermatology</i> 188: 13-17 (1994)				ite in Homogenized Living
126 Kung and Redemann, Biochim. Biophys. Acta 862: 435-439 (1986)					
a	Lamont et al., "The use of Peptide Analogs with Improved Stability and MHC Binding Capacity to Inhibit Antigen Presentation In Vitro and In Vivo," J. Immunol. 144: 2493-2498 (1990)				
Ex	Examiner Date Considered 4/9/ry				

Form PTO-1449 U.S. Department of Common Patent and Trademark (INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
Lanzavecchia et al., "Irreversible ass cells," Nature 357: 249-252 (1992)	ciation of peptides with class II MHC molecules in living				
	Larsen et al., "Stability of ketoprofen-dextran ester prodrugs in homogenates of various segments of the pig GI tract," <i>Acta Pharm. Nord.</i> 3: 41-44 (1991)				
	Lee et al., "Antibacterial peptides from pig intestines: Isolation of a mamalian cecropin," <i>Proc. Natl. Acad. Sci. USA</i> <u>86</u> : 9159-9162 (1989)				
132 Lehrer et al., "Defensins: Endogenom (1991)	,,,,,,,,				
cellulose acetate; (ii) effect of temper	Lin et al., "Preparation of Enteric-Coated Microspheres of myplasma hyopneumoniae vaccine with cellulose acetate; (ii) effect of temperature and ph on the stability and release behaviour of microspheres," <i>Journal of Microencapsulation</i> , Vol. 8, No. 4: 537-545 (1991)				
Lipozencic et al., "Langerhans cells i Histochem 38: 303-310 (1994)]				
Examiner Date Considered Date Considered					

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Atty. Docket No. 90,663-QQ Applicant: Yatvin et al. Filing Date: 1-15-2002	Serial No. 10/050,271 Group: 1651		
135	Loughery et al., J. Immunol. Methods 132:				
136	MacDonald, J. Biol. Chem. 265: 13533-13	539 (1990)			
137	137 Maciejewski et al., "Infection of Mononucleated Phagocytes with Human Cytomegalovirus," Vin 195: 327-336 (1993)				
138	Matsura et al., J. Chem. Soc. Chem. Comm.	. x <u>x</u> : 451-459 (1976)			
139 Mauel et al., "Quantitative Release of Live Micro-organisms from Infected Ma Sodium Dodecyl Sulfate," <i>Nature New Biol.</i> 244:93-94 (1973)			ed Macrophages by		
140	Mauel, "Macrophage-Parasite Interactions in Leishmania Infections," J. Leukocyte Biol. 47: 187-193 (1990)				
an 141	McEntee et al., "Rhesus monkey macrophages infected with simian immunodeficiency virus cause rapid lysis of CD4-bearing lymphocytes," J. Gen. Virol. 72: 317-324 (1991)				
Examin r					

	Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Atty. Docket No. 90,663-QQ	Serial No. 10/050,271
				Applicant: Yatvin et al.	
				Filing Date: 1-15-2002	Group: 1651
	W	142	Meltzer and Gendelman, "Mononuclear Philipment Immunoregulatory Cells in Human Immunol. 181: 239-263 (1992)		
		143	Menger et al., "Synthesis of a Lipid/Peptide Bioconjugate Chemistry 5: 162-166 (1994))	
		144	Moehrle et al., "Aminopeptidase M and dip histochemical study," J. Cutaneous Patholo	peptidyl peptidase IV activity in epithelial skin tumors: a logy 22: 241-247 (1995)	
	7	145	Mukhergee & Heidelberger, Cancer Res. 22		
		146			
		147	Narayan et al., "Lentivirus Induced Arthriti	s in Animals," J. Rheumatol.	32 :25-32 (1992)
		148	Negre et al., "Antileishmanial Drug Targeti Internalized by Macrophage Membrane Lec 2232 (1992)		•
		149	Neto et al., Biochem. Biophys. Res. Commu	n. <u>171</u> : 458-464 (1990)	
		150	Neurath et al., J. Gen. Virol. 65:1009-1014	(1984)	
		151	Ng & Heath, Biochim. Biophys. Acta 981:	261-268 (1989)	
		152	Nogueira and Cohn, "Trypanosoma cruzi: Mammalian Cells," J. Exp. Med. 143:1402-	•	acellular Fate in
		153	Nothnagel, Biochim. Biophys. Acta 980: 20	09-219 (1989)	
		154	Pagano et al., J. Biol. Chem. 258: 2034-20-	40 (1983)	
		155	Panuska et al., "Productive Infection of Isol Syncytial Virus," J. Clin. Invest. <u>86</u> : 113-1		phages by Respiratory
		156	Pardridge, "Opioid Peptide Drug Developm Blood-Brain Barrier," NIDA Res. Monogra	ph <u>120</u> : 153-168 (1992)	meric Peptides through the
9	24-	157	Parham, "Transporters of delight," Nature	<u>348</u> : 674-675 (1990)	
	Exami	ner		Date Considered	

Fo	Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Atty. Docket No. 90,663-QQ	Serial No. 10/050,271	
				Applicant: Yatvin et al.		
				Filing Date: 1-15-2002	Group: 1651	
a,)	158	Paul and Anderson, J. Am. Chem. Soc. 82:	4596-4600 (1960)		
		159	Payne et al., "Phagocytosis of Legionella procession of Complement Receptors," J. Exp. Med. 166:	: 1377-1389 (1987)	uman Monocyte	
Ш		160	Rahman et al., <i>Life Sci.</i> 31: 2061-2071 (19			
		161	Remy et al., J. Org. Chem. 27: 2491-2500 (
Ш		162	Rosenberg et al., J. Neurochem. 48: 865-87			
	Rowlinson-Busza and Epenetos, "Targeted delivery of biologic and other antineoplastic agents, Curr. Opin. Oncol. 4: 1142-1148 (1992)					
	Rubinstein et al., "In Vitro Evaluation of Calcium Pectinate: A Potential Colon-Specific Drug Delivery Carrier," Pharm. Res. 10: 258-263 (1993)				Colon-Specific Drug	
	Sadegh-Nasseri and Germain, "A role for peptide in determining MHC class II structure," <i>Natur</i> 353: 167-170 (1991)				ass II structure," Nature	
	Saffran et al., "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs Science 233: 1081-1084 (1986)				d Other Peptide Drugs,"	
\prod		167	Salord et al., Biochim. Biophys. Acta 886:	64-75 (1986)		
	Schlessinger and Horwitz, "Phagocytosis of Leprosy Bacilli is Mediated by Complement Recepted CR1 and CR3 on Human Monocytes and Complement Component C3 in Serum," J. Clin. Investing 55: 1304-1314 (1990)					
	Schmitt et al., "Multiplication of Human Immunodeficiency Virus in Primary Cultures of Human Kupffer Cells - Possible Role of Liver Macrophage Infection in the Physiopathology of AIDS," Re Virol. 141: 143-152 (1990)					
	Schnorr et al., "MxA-Dependent Inhibition of Measles Virus Glycoprotein Synthesis in a Stably Transfected Human Monocytic Cell Line," J. Virol. 67: 4760-4768 (1993)					
		171 Seifert et al., Biochem. J. 267:795-802 (1990)				
		Sellon et al., "Wild-Type Equine Infectious Anemia Virus Replicates in Vivo Predominantly in Tissue Macrophages, Not in Peripheral Blood Monocytes," J. Virol. 66: 5906-5913 (1992)				
	Senter et al., "Activation of Prodrugs by Antibody-Enzyme Conjugates," in Immunobiology of Peptides and Proteins, Vol. VI, pp. 97-105 (1991)				in Immunobiology of	
Ž	Shanley and Pesanti, "Murine Peritoneal Macrophages Support Murine Cytomegalovirus Replication," Infect. Immunol. 41: 1352-1359 (1983)				ytomegalovirus	

R		175	Shen et al., "Cis-Aconityl Spacer between Daunomycin and Macromolecular Carriers: A Model of pH Sensitive Linkage Releasing Drug from a Lysomotropic Conjugate," <i>Biochem. Biopys. Res. Commun.</i> 102:1048-1052 (1981)		
П		176	Sierra-Honigman et al., "Borna disease virus in peripheral blood mononuclear and bone marrow cells of neonatally and chronically infected rats," <i>J. Neuroimmunol.</i> 45: 31-36 (1993)		
		177	Sintov et al., "Enzymatic cleavage of disaccharaide side groups in insoluble synthetic polymers: a new method for specific delivery of drugs to the colon," <i>Biomaterials</i> 14: 483-490 (1993)		
		178	SivaSai et al., "Effect of Recombinant Interferon Gamma Administration on Lesional Monocytes/Macrophages in Lepromatous Leprosy Patients," Int. J. Leprosy & Other Mycobacterial Diseases 61: 259-269 (1993)		
Π	180 Smith and Khorana, J. Amer. Chem. Soc. <u>80</u> : 1141-1145 (1958)				
才	181 Steim et al., Biochem. Biophys. Res. Commun. 171: 451-457 (1990)				
Examin r Date Considered					

Form		9 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No. 90,663-QQ Applicant: Yatvin et al.	Serial No. 10/050,271	
			Filing Date: 1-15-2002	Group: 1651	
m	182	Strellrecht-Broomhall, "Evidence for Immu Induced Anemia in Persistently Infected Mi	_		
183 Sturgill-Koszycki et al., "Lack of Acidific Exclusion of the Vesicular Proton-ATPase			tion in <i>Mycobacterium</i> Phagosomes Produced by "Science 263: 678-681 (1994)		
reversable by ly		•	daunorubicin and proteins that is stable in serum and uired for a lysomotropic drug-carrier conjugate: In vitro i. USA 79:626-629 (1982)		
	185	van Wijk et al., Biochim. Biophys. Acta 108	<u>34</u> : 307-310 (1991)		
	186	Vandenbark et al., Nature 341:841-844 (19	89)		
	187	Verbloom et al., Synthesis 1032: 807-809 (1981)		
		Wada et al., "Salt Formation of Lactic Acid J. Pharm. Pharmacol. 43: 605-608 (1991)	Oligomers as Matrix for Su	stained Release of Drugs,"	
	189	Wiesmüller et al., "The antibody response is circumsporozoite repetitive epitope covalen 72: 109-113 (1991)		<i>y</i> ,	
Exami	ner _	Du. M.	ate Considered		

Form PTO-	U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT	1 7	Serial No. 10/050,271		
		Applicant: Yatvin et al.			
		Filing Date: 1-15-2002	Group: 1651		
a 190	Wyrick and Brownridge, "Growth of Chlamydia psittaci in Macrophages," Infect. Immunol. 19:1054-1060 (1978)				
193	191 Yatvin et al., "Targeting Lipophilic Prodrugs to Brain, Lung, and Spleen," Journal of Cellular Biochemistry, Vol. 0, No. 19A: 173 (1995)				
192	Yatvin, "A Multi-Modality Approach for the Treatment of AIDS," Select. Cancer. Therapeut. 7: 23-28 (1991)				
193	Zasloff, "Magainins, a class of antimicrobial peptides from <i>Xenopus</i> skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor," <i>Proc. Natl. Acad. Sci USA</i> 84: 5449-5453 (1987)				
Zhang and McCormick, "Uptake of N-(4'-pyridoxyl)amines and release of amines by renal cells: A model for transporter-enhanced delivery of bioactive compounds," <i>Proc. Natl. Acad. Sci. USA</i> 88: 10407-10410 (1991)					
Examiner Date Considered 19/0 EXAMINER: Initial if citation considered whether or not citation is in conformance with MRER 600. Days like the series is for a few and the series is few and the series is for a few and the series is for a few and the series is few and the s					